ReviewCurrent oncology reports2018
Toxicity of Cancer Therapies in Older Patients.
Review in Current oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Frailty and long-term survival of patients with ovarian cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Nomograms for predicting overall survival and cancer-specific survival in elderly patients with epithelial ovarian cancer.Journal of ovarian research · 2023Trial
- Trial
- Personalized prognosis: construction and validation of a survival prediction model for older postoperative differentiated thyroid cancer patients.BMC geriatrics · 2026Article
- Aging with leukemia: public health strategies for optimizing quality of life and palliative care in refractory cases.Annals of medicine and surgery (2012) · 2025Review
- Serious Gaming for Chemotherapy-Induced Nausea and Vomiting in Older Adults With Cancer: Protocol for a Randomized Clinical Trial.JMIR research protocols · 2024Article
- Article
- Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol.Diagnostics (Basel, Switzerland) · 2024Article
- Oxathiazinane derivatives display both antineoplastic and antibacterial activity: a structure activity study.Journal of cancer research and clinical oncology · 2023Article
- Article
- Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review.Cancers · 2023Review
- Article
- Application of lipid nanovesicle drug delivery system in cancer immunotherapy.Journal of nanobiotechnology · 2022Review
- Clinical Characteristics, Prognostic Factor and a Novel Dynamic Prediction Model for Overall Survival of Elderly Patients With Chondrosarcoma: A Population-Based Study.Frontiers in public health · 2022Article
- Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.Blood advances · 2020Review
- Acute Toxicities and Prognosis of Elderly Patients with Nasopharyngeal Carcinoma After Intensity-Modulated Radiotherapy: Prediction with Nomogram.Cancer management and research · 2020Article
- Research Progress on Chemical Constituents and Anticancer Pharmacological Activities ofBioMed research international · 2020Review
- Bee Collected Pollen and Bee Bread: Bioactive Constituents and Health Benefits.Antioxidants (Basel, Switzerland) · 2019Review
- Synthesis of Chalcone Derivatives: Inducing Apoptosis of HepG2 CellsFrontiers in pharmacology · 2019Article
- Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewIn clinical practice, older patients are often undertreated due to underrepresentation in clinical trials and fear of toxicity. Our objective was therefore to review toxicities that are specific to older cancer patients, to review risk factors in order to help physicians guide their decisions, and to review interventions that can be implemented in routine clinical practice to prevent toxicity induced by cancer therapies. RECENT
findingsOn the whole, reviews report similar number and frequency as well as similar grade 3 or 4 adverse events between subjects older and younger than 65 years. Yet patients included in clinical trials are often not representative of real-life patients and are often fit older cancer patients. Moreover, tolerance to the additive impact of multiple adverse effects is different between older and younger patients. And specific symptoms such as stomatitis may cause a series of consequences such as dehydration, denutrition, renal insufficiency, and adverse events of renally excreted drugs. Older patients are at high risk of toxicity due to many factors but mainly due to the prevalence of frailty in this population that has been estimated to be around 40% increasing the risk of chemotherapy intolerance. As a consequence, interventions must be implemented according to altered domains of comprehensive geriatric assessment in order to improve anticancer tolerance. These interventions are reviewed here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.